MedPath
HSA Approval

TUSSIDEX FORTE LINCTUS 15 mg/5 ml

SIN06770P

TUSSIDEX FORTE LINCTUS 15 mg/5 ml

TUSSIDEX FORTE LINCTUS 15 mg/5 ml

January 21, 1992

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.
Licence HolderAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

ELIXIR

ORAL

Medical Information

R05DA09

dextromethorphan

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

DEXTROMETHORPHAN HBr

15 mg/5 ml

Dextromethorphan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TUSSIDEX FORTE LINCTUS 15 mg/5 ml - HSA Approval | MedPath